Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217970 · ClinicalTrials.gov registry record · Phase 1
Safety Interaction Trial Ibudilast and Methamphetamine
A Phase 1 study of Substance Abuse and Methamphetamine-dependence, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01217970 is a Phase 1 study of Substance Abuse and Methamphetamine-dependence that has completed, run by University of California, Los Angeles. The registered enrollment target is 11 participants, below the 5,260-participant average among 58 other Substance Abuse trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01217970, a Phase 1 study of Substance Abuse and Methamphetamine-dependence, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to collect data to determine whether a medication, ibudilast, is safe for use as a potential treatment for methamphetamine-dependent people. For 18 years in Japan and South Korea, ibudilast has been used safely in humans as a treatment for asthma, pulmonary, and cardiovascular disease. It is not known whether ibudilast is safe to use in outpatient settings with people who have methamphetamine dependence. This would be the first study to collect this information. This study is important because individuals with methamphetamine dependence often relapse to meth use, even when in treatment; some number of individuals who participate in an outpatient study will relapse to methamphetamine while taking ibudilast. It is crucial to know whether there may be interactions between ibudilast and methamphetamine before planning an outpatient clinical trial.Ibudilast is an exciting medication candidate for treating methamphetamine dependence. When individuals become abstinent from methamphetamine during early recovery, the body starts an inflammatory process in neurons, especially glial cells. Glial cells are important in that they provide support to the nerve cells that are involved in thought, movement, and other human activities. By dampening inflammation in glial cells, ibudilast may preserve glial and other nerve cells during early abstinence, which in turn may help individuals feel better and think better during treatment. The study specific aims are to determine whether ibudilast alters: 1. blood pressure and heart rate responses to methamphetamine; 2. the ratings of craving or other drug experiences from methamphetamine; 3. the reward/reinforcing effects of methamphetamine; and 4. the metabolism of methamphetamine. Over an enrollment period of 24 months, 12 methamphetamine-dependent participants who are not looking for treatment will complete this study.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Ibudilast 20mg
- DRUG Ibudilast 50mg
Study Locations (1)
California
- Harbor-UCLA Medical Center GCRC - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217970
The ClinicalTrials.gov registry entry for NCT01217970 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,260-participant average among 58 other Substance Abuse trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Substance Abuse appearing as the primary indexed condition, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT01217970 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01217970 about?
NCT01217970 is a clinical study titled "Safety Interaction Trial Ibudilast and Methamphetamine". This study is designed to collect data to determine whether a medication, ibudilast, is safe for use as a potential treatment for methamphetamine-dependent people. For 18 years in Japan and South Korea, ibudilast has been used safely in humans as a treatment for asthma, pulmonary, and cardiovascular...
What is the current status of trial NCT01217970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-01. Estimated completion is 2013-03.
What conditions does trial NCT01217970 study?
This clinical trial studies the following conditions: Substance Abuse, Methamphetamine-dependence.
What interventions are being tested in trial NCT01217970?
The interventions under investigation include: Placebo oral tablet (DRUG), Ibudilast 20mg (DRUG), Ibudilast 50mg (DRUG).
Who is sponsoring clinical trial NCT01217970?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01217970 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use
COMPLETED · Phase 1
-
Computer Based Training in Cognitive Behavioral Therapy Web-based
COMPLETED · Phase 1
-
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
COMPLETED · Phase 1
-
Adolescent Involvement in Parental Substance Abuse Treatment
COMPLETED · Phase 1
-
Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education
COMPLETED · Phase 1
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.